Gilead Stock News

Gilead Sciences, Inc. (GILD) with the stream of 0.54% also noticed, India Oracle Corporation (ORCL) encountered a rapid change of 0.66% in the last hour of Monday’s trading session. Gilead … The post Sector Declining Stock: Gilead Sciences, Inc. (NASDAQ:GILD), Oracle Corporation (NYSE:ORCL) appeared first on Stocks Equity .

Biopharmaceutical company Gilead Sciences has chosen Amazon Web Services as its cloud provider, AWS announced Monday (Nov. 29). Innovating on AWS and with the help of AWS experts and partners in healthcare and life sciences, Gilead provides its data scientists with the latest advances in machine learning and analytics, the company said in a news []

Gilead Sciences Inc. (NASDAQ:GILD) traded at $70.27 at close of the session on Friday, 11/26/21, made an upward move of 0.29% on its previous days price. Looking at the stock we see that its previous close was $70.07 and the beta (5Y monthly) reads 0.41 with the days price range being $69.70 $70.74. The Gilead Sciences Inc. (NASDAQ: GILD) Has Been Trading Down. What Are The Prospects For The Future? Read More »

Polaris Wealth Advisory Group LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 405,666 shares of the biopharmaceutical companys stock after selling 109,409 shares during the period. Gilead []

Biopharmaceutical company Gilead Sciences has chosen Amazon Web Services as its cloud provider, AWS announced Monday (Nov. 29). “Innovating on AWS and with the help of AWS experts and partners in he

NRx Pharmaceuticals (NASDAQ: NRXP ) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc''s (NASDAQ: GILD ) remdesivir in the COVID-AIV trial representing approximately 70% of the study population. The analysis indicates a substantial improvement after Zyesami (aviptadil) treatment in patients with critical COVID-19 and Respiratory Failure over existing therapies. Read Next: Full story available on Benzinga.com

Private Advisor Group LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.7% in the third quarter, Holdings Channel reports. The institutional investor owned 139,737 shares of the biopharmaceutical companys stock after acquiring an additional 56,904 shares during the period. Private Advisor Group LLCs holdings in Gilead Sciences were worth $9,761,000 as []

Gilead Sciences, Inc. (GILD) with the stream of 0.29% also noticed, India Manulife Financial Corporation (MFC) encountered a rapid change of -2.71% in the last hour of trading session. Gilead The post Todays Hot Mover: Gilead Sciences, Inc. (NASDAQ:GILD), Manulife Financial Corporation (NYSE:MFC) appeared first on Stocks Equity .

Phunware, Inc. (PHUN) with the stream of -2.35% also noticed, India Cameco Corporation (CCJ) encountered a rapid change of -4.60% in the last hour of trading session. Phunware, Inc. (NASDAQ:PHUN) The post Gilead Sciences, Inc., NASDAQ:GILD, GILD NEWS, GILD STOCK, Manulife Financial Corporation, NYSE:MFC, MFC NEWS, MFC STOCK, GILD, MFC appeared first on Stocks Equity .

DNB Asset Management AS cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 316,814 shares of the biopharmaceutical companys stock after selling 651 shares during the quarter. DNB Asset Management ASs []

Twin Lakes Capital Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,822 shares of the biopharmaceutical companys stock after purchasing an additional 472 shares during the quarter. Gilead Sciences []

Pacer Advisors Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 419,503 shares of the biopharmaceutical companys stock after purchasing an additional 52,013 shares during the period. Pacer Advisors Inc.s holdings in Gilead Sciences []

Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.

Crossmark Global Holdings Inc. reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 77.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 44,058 shares of the biopharmaceutical companys stock after selling 151,608 shares during the quarter. Crossmark Global Holdings []

Brokerages expect that Gilead Sciences, Inc. (NASDAQ:GILD) will announce $6.39 billion in sales for the current quarter, Zacks reports. Seven analysts have issued estimates for Gilead Sciences earnings. The lowest sales estimate is $6.22 billion and the highest is $6.69 billion. Gilead Sciences reported sales of $7.42 billion during the same quarter last year, which []